cytomegaloviru
cmv
may
relev
caus
morbid
patient
display
variou
inflammatori
diseas
studi
investig
whether
cmv
dna
detect
lower
respiratori
tract
system
compart
pediatr
patient
chronic
recurr
bronchopulmonari
diseas
total
lower
respiratori
tract
specimen
pair
plasma
sampl
patient
analyz
presenc
cmv
dna
realtim
pcr
respiratori
specimen
also
screen
presenc
respiratori
virus
human
herpesviru
pcr
method
quantit
bacteri
fungal
cultur
perform
level
respiratori
specimen
quantifi
use
elisa
cmv
dna
detect
either
lower
respiratori
airway
plasma
cmvseroposit
patient
level
significantli
higher
patient
detect
level
cmv
dna
dna
detect
three
one
patient
respect
respiratori
virus
detect
patient
signific
growth
one
bacteri
speci
observ
patient
signific
associ
found
presenc
cmv
dna
detect
microorgan
data
indic
presenc
cmv
dna
lower
respiratori
tract
frequent
find
children
chronic
recurr
bronchopulmonari
diseas
prospect
observ
studi
need
assess
impact
phenomenon
clinic
cours
patient
cytomegaloviru
cmv
infect
lead
caus
morbid
mortal
sever
immunosuppress
patient
undergo
allogen
hematopoiet
stem
cell
solid
organ
transplant
solano
navarro
nevertheless
recent
data
suggest
cmv
may
also
relev
caus
morbid
patient
lack
canon
immunosuppress
display
variou
inflammatori
process
includ
cardiovascular
autoimmun
chronic
bowel
diseas
ez
et
al
ez
et
al
patient
activ
cmv
infect
detect
frequent
either
inflam
tissu
even
blood
compart
furthermor
activ
cmv
infect
either
restrict
lower
respiratori
tract
involv
lower
respiratori
airway
system
compart
shown
occur
frequent
critic
ill
adult
cmvseroposit
patient
blanquer
et
al
associ
prolong
intens
care
unit
hospit
extend
period
mechan
ventil
higher
rate
nosocomi
infect
overal
mortal
review
see
kalil
florescu
pathogenet
perspect
data
obtain
murin
cmv
model
indic
proinflammatori
state
critic
factor
promot
cmv
replic
cook
et
al
tnfa
cytokin
known
transactiv
express
cmv
immediateearli
gene
play
critic
role
trigger
cmv
reactiv
et
al
context
activ
cmv
infect
may
occur
pediatr
patient
chronic
recurr
bronchopulmonari
diseas
inflamm
play
potenti
major
pathogen
role
current
studi
undertaken
investig
hypothesi
total
lower
respiratori
tract
specimen
bronchoaspir
n
bronchoalveolar
lavag
n
tracheal
aspir
n
pair
plasma
sampl
children
femal
male
median
age
year
old
rang
month
year
old
attend
pneumolog
unit
univers
clinic
hospit
valencia
analyz
patient
previou
histori
chronicrecurr
lower
tract
respiratori
symptom
andor
persistentrecurr
radiograph
abnorm
infiltr
telectasi
air
trap
imag
fibrobronchoscopi
perform
may
juli
either
primari
diagnosi
diagnosi
reevalu
patient
respond
unsatisfactorili
convent
therapi
complementari
diagnost
procedur
assess
erad
pseudomona
aeruginosa
cystic
fibrosi
patient
neg
sputum
cultur
cours
antibiot
therapi
accord
local
protocol
patient
acut
upper
lower
respiratori
tract
sign
symptom
time
fibrobronchoscopi
patient
follow
underli
bronchopulmonari
condit
atelectasi
round
middl
lobe
syndrom
n
cystic
fibrosi
n
bronchiectasi
n
chronic
asthma
respond
convent
treatment
n
tracheomalacia
n
bronchiol
obliteran
n
chronic
interstiti
pneumopathi
n
bronchopulmonari
dysplasia
n
bronchial
hypoplasia
n
patient
lack
known
caus
immunosuppress
lower
respiratori
tract
specimen
process
use
convent
quantit
bacteri
fungal
cultur
growth
cfuml
bacteri
fungal
speci
bronchoaspit
bronchoalveolar
lavag
respect
consid
signific
microbi
identif
accomplish
convent
procedur
patient
molecular
detect
respiratori
virus
also
perform
shortli
fibrobronchoscopi
bronchoalveolar
lavag
bronchial
tracheal
aspir
pretreat
dithiothreitol
ratio
ml
g
bronchoaspir
vortex
centrifug
min
pellet
cell
cell
supernat
store
retriev
molecular
analys
cytokin
measur
serum
specimen
assess
cmvserostatu
avail
patient
specimen
obtain
either
prior
time
fibrobronchoscopi
sera
frozen
retriev
serolog
test
studi
conform
ethic
guidelin
declar
helsinki
approv
local
ethic
committe
written
inform
consent
obtain
parent
cmv
dna
load
quantifi
realtim
pcr
abbott
cmv
pcr
kit
produc
qiagen
gmbh
hilden
germani
abbott
diagnost
de
plain
il
previous
describ
gimeno
et
al
chilet
et
al
bravo
et
al
assay
abl
reliabl
quantifi
cmv
dna
load
copiesml
dna
extract
perform
volum
ml
plasma
lower
respiratori
tract
specimen
use
abbott
msampl
prepar
system
dna
kit
sp
instrument
abbott
molecular
il
detect
quantif
human
human
perform
respiratori
specimen
realtim
pcr
realqual
ab
analitica
padova
itali
detect
limit
assay
approxim
copiesml
dna
extract
respiratori
specimen
ml
use
viru
kit
qiagen
valencia
ca
biorobot
extract
platform
qiagen
follow
manufactur
instruct
detect
respiratori
virus
perform
multiplex
pcr
use
rvp
fast
assay
luminex
molecular
diagnost
toronto
canada
follow
manufactur
instruct
analysi
perform
use
xmap
instrument
luminex
molecular
diagnost
rvp
fast
assay
simultan
detect
influenza
viru
subtyp
influenza
b
viru
rsva
b
adenoviru
human
metapneumoviru
coronavirus
enteroviru
rhinoviru
human
bocaviru
nucleic
acid
extract
perform
ml
respiratori
sampl
viru
kit
biorobot
commerci
captur
immunoassay
use
quantifi
respiratori
specimen
human
elisa
readyset
go
ebiosci
san
diego
ca
follow
manufactur
instruct
bronchoalveolar
lavag
specimen
epitheli
line
fluid
volum
calcul
use
urea
dilut
marker
zedtwitzliebenstein
et
al
detect
limit
assay
pgml
cmv
igg
detect
use
diasorin
liaison
cmv
igg
assay
diasorin
saluggia
itali
data
analyz
aid
spss
statist
packag
version
spss
north
chicago
il
comparison
undertaken
use
x
categor
variabl
nonparametr
mannwhitney
utest
unpair
continu
data
twosid
exact
p
valu
present
p
valu
consid
statist
signific
eleven
patient
cmvseroposit
time
fibrobronchoscopi
cmvseroneg
cmvserostatu
unknown
presenc
cmvdna
lower
respiratori
tract
specimen
assess
patient
detect
six
cmvseroposit
patient
median
copiesml
rang
copiesml
none
remain
patient
presenc
cmv
dna
blood
compart
plasma
investig
exclus
cmvseroposit
patient
plasma
cmv
dnaemia
detect
two
patient
patient
cmv
dna
also
detect
lower
respiratori
tract
clinic
microbiolog
featur
patient
shown
tabl
noteworthi
two
three
patient
cystic
fibrosi
cmvseroposit
time
fibrobronchoscopi
cmv
dna
detect
lower
respiratori
tract
despit
fact
five
six
patient
cmv
dna
detect
lower
respiratori
tract
corticosteroid
treatment
time
fibrobronchoscopi
fluticason
signific
associ
found
use
corticosteroid
detect
cmv
dna
p
comprehens
microbiolog
analysi
lower
respiratori
tract
specimen
patient
perform
presenc
respiratori
virus
investig
multiplex
pcr
occurr
common
bacteri
fungal
speci
assess
convent
cultur
method
respiratori
virus
detect
patient
rhinoviru
n
respiratori
syncyti
viru
n
bocaviru
n
metapneumoviru
n
coronavirus
n
adenoviru
n
two
patient
test
posit
cmv
dna
lower
respiratori
tract
signific
growth
one
bacteri
speci
observ
patient
haemophilu
influenza
biotyp
viii
iii
n
staphylococcu
aureu
n
streptococcu
pneumonia
n
moraxella
catharrali
n
pseudomona
aeruginosa
n
achromobact
xyloxosidan
n
candida
parapsilosi
isol
three
patient
two
six
patient
detect
cmv
dna
posit
bacteri
cultur
signific
correl
p
found
presenc
cmv
dna
infect
respiratori
virus
bacteri
fungal
speci
either
patient
consid
collect
irrespect
cmv
serostatu
subgroup
cmvseroposit
patient
analyz
separ
presenc
dna
lower
respiratori
tract
assess
cmvseroposit
patient
dna
detect
three
patient
copiesml
two
cmv
dna
present
lower
respiratori
tract
dna
detect
one
patient
copiesml
cmv
dna
detect
lower
respiratori
tract
shown
reliabl
marker
inflamm
lower
respiratori
airway
level
lower
respiratori
tract
specimen
quantifi
patient
shown
figur
significantli
higher
level
p
found
patient
detect
cmv
dna
median
pgml
rang
pgml
compar
patient
without
median
pgml
rang
pgml
differ
level
found
cmvseroposit
patient
detect
cmv
dna
patient
known
cmvseroneg
p
activ
cmv
infect
known
occur
frequent
adult
patient
lack
canon
immunosuppress
inflammatori
diseas
may
lead
increas
morbid
current
studi
investig
whether
cmv
dna
detect
lower
respiratori
tract
plasma
children
variou
underli
bronchopulmonari
diseas
character
presenc
chronic
recurr
inflamm
lower
respiratori
airway
overal
cmv
dna
detect
lower
respiratori
tract
patient
howev
percentag
increas
patient
known
cmvseroposit
time
fibrobronchoscopi
consid
lung
major
site
cmv
latenc
cook
et
al
would
interest
know
rate
cmv
dna
detect
lower
respiratori
tract
healthi
cmvseroposit
children
highli
unlik
though
high
found
studi
involv
system
compart
demonstr
two
six
patient
detect
cmv
dna
lower
respiratori
tract
low
cmv
dna
load
usual
observ
compart
scenario
resembl
seen
critic
ill
patient
subject
mechan
ventil
patient
demonstr
rapid
expans
cmvspecif
function
cell
occur
upon
cmv
reactiv
keep
viral
load
low
level
compart
eventu
control
episod
blanquer
et
al
particularli
noteworthi
discoveri
cmv
dna
detect
lower
respiratori
tract
two
three
cmvseroposit
cystic
fibrosi
patient
level
lower
respiratori
tract
significantli
higher
patient
detect
cmv
dna
without
support
possibl
bidirect
pathogen
relationship
cmv
inflamm
replic
also
detect
lower
respiratori
tract
patient
activ
cmv
infect
turn
activ
infect
detect
cmvseroposit
patient
consist
assumpt
proinflammatori
state
also
may
trigger
reactiv
betaherp
virus
may
turn
result
increas
net
inflammatori
state
lower
respiratori
tract
flamand
et
al
part
routin
systemat
analysi
lower
tract
specimen
patient
pcr
analys
perform
detect
respiratori
virus
addit
convent
bacteri
fungal
cultur
despit
stabl
clinic
condit
patient
time
fibrobronchoscopi
respiratori
virus
detect
almost
onethird
patient
although
contamin
virus
present
upper
respiratori
tract
could
formal
exclud
featur
consist
either
delay
clearanc
recent
acut
viral
infect
episod
persist
viral
infect
lower
respiratori
airway
plausibl
latter
explan
support
data
obtain
experiment
anim
model
also
human
respiratori
syncyti
viru
rhinoviru
human
metapneumoviru
infect
schwarz
et
al
liu
et
al
persist
replic
virus
lower
respiratori
tract
induc
inflamm
papadopoulo
et
al
may
therebi
promot
local
cmv
reactiv
turn
cmv
may
also
potenti
respiratori
viru
replic
lower
respiratori
tract
virtu
immunosuppress
capac
solano
navarro
nevertheless
signific
associ
found
presenc
cmv
dna
lower
respiratori
tract
occurr
respiratori
virus
likewis
occurr
activ
cmv
infect
critic
ill
patient
relat
increas
incid
bacteri
fungal
super
infect
jaber
et
al
chich
et
al
current
investig
also
found
associ
presenc
cmv
dna
lower
respiratori
tract
occurr
bacteri
fungal
speci
howev
studi
specif
design
investig
potenti
pathogen
interact
definit
conclus
may
drawn
issu
current
studi
sever
limit
firstli
crosssect
studi
limit
sampl
size
secondli
includ
highli
heterogen
cohort
thirdli
given
retrospect
natur
cmvserostatu
unknown
larg
number
patient
fourthli
although
cell
supernat
use
pcr
analys
possibl
detect
cmv
dna
reflect
latent
rather
activ
viral
infect
patient
special
low
cmv
dna
load
could
formal
rule
neither
detect
viral
mrna
inocul
convent
cell
cultur
recoveri
live
viru
perform
nevertheless
data
report
warrant
prospect
observ
studi
confirm
find
present
explor
possibl
exist
pathogenet
interact
cmv
respiratori
virus
bacteri
fungal
speci
colon
lower
respiratori
airway
patient
assess
potenti
impact
cmv
replic
lower
respiratori
tract
clinic
cours
outcom
patient
light
data
present
children
cystic
fibrosi
primari
focu
studi
